Cicatridina is commonly used across domains involving physical tissue injury and mucosal compromise, relevant to providing symptomatic relief. Topical hyaluronic acid preparations are relevant for the management of wounds, skin ulcers, and the relief of symptoms like burning, itching, and pain in various dermatoses.

The product is applied to support recovery in post-procedural and traumatic tissue damage, helping to manage symptoms that arise when the skin or mucous membranes are compromised. The product is generally used in situations involving recurrent or episodic manifestations, applied in scenarios where additional management of discomfort is required, such as everyday abrasions, minor burns, cuts, post-surgical lesions, anal fissures, vaginal atrophy, and chronic non-healing ulcers. Furthermore, it is relevant for easing discomfort of atrophic and fissure-related symptoms in the gynecological and anorectal areas.

“The product may be relevant in clinical settings that involve acute or unstable symptom patterns, particularly where symptoms relate to compromised tissue integrity.”

The overall therapeutic benefit is to provide supportive relief that helps maintain a sense of stability when symptoms are more noticeable, relevant to the body’s own healing process. It provides supportive relief when symptoms interfere with routine activities, contributing to easing the overall symptom load during symptomatic periods.

Quick Fact: Relief for Localized Tissue Discomfort

Regulatory References

1. overview published by the National Institutes of Health (NIH)

Who Can and Cannot Use Cicatridina?

Cicatridina is primarily regulated as a Medical Device for local application, resulting in eligibility rules centered on local factors rather than systemic patient conditions. Regulatory documentation defines populations who can use the device and those who must be excluded.

Eligibility Summary

Eligibility Scope

No restrictions related to systemic organ function, such as hepatic or renal impairment, are documented in the labeling, consistent with its non-systemic mode of action. Eligibility is broadly inclusive for approved age groups, subject to the single absolute exclusion of hypersensitivity.

Interactions with other medicines and products

Interactions with Cicatridina are primarily governed by the product's classification as a locally applied Medical Device with minimal systemic absorption, leading to an absence of documented systemic drug interactions.

Official Interaction Pattern: Local Chemical Incompatibility

The only official documented interaction pattern is a local physical and chemical incompatibility that affects the product's function at the application site. This constraint is crucial for the appropriate administration of the product.

Co-administration with local antiseptics or disinfectants that contain Quaternary Ammonium Compounds (such as Benzalkonium Chloride or Cetylpyridinium Chloride) causes the precipitation of the active ingredient, Sodium Hyaluronate. This reaction results in a functional loss of the product's intended properties.

Restrictions on Administration Timing

The chemical incompatibility necessitates a mandatory timing separation rule. The product must not be used simultaneously with any local product containing a quaternary ammonium compound. This regulatory restriction ensures the active ingredient retains its structural integrity and functional capacity.

Absence of Systemic Interactions

No interactions involving systemic metabolic pathways (e.g., CYP enzymes, drug transporters) are documented in official regulatory labeling. Furthermore, no specific interactions with food, alcohol, or dietary supplements are officially cited.

The mechanism of action for Cicatridina operates through core, complementary biological domains: providing structural support and mediating cellular signaling to modulate the physiological microenvironment. The primary constituent, Sodium Hyaluronate, acts as a structural polymer, binding large amounts of water to form a localized, highly viscoelastic matrix that serves as a temporary scaffold in the defect area. This process facilitates high levels of water binding and physical protection, contributing to the early phases of the repair cascade. Beyond this physicochemical role, Sodium Hyaluronate binds to cell surface receptors, such as CD44 on fibroblasts and keratinocytes, initiating signaling pathways that influence cell motility and proliferation. Complementary bio-stimulatory effects from botanical components increase the rate of collagen Type I and III synthesis. This modulation of synthesis, coupled with the control of anti-reparative factors like TGF-beta, influences the characteristics of the new matrix formation, supporting the establishment of increased structural organization and functional integrity in the tissue.

The administration protocol for Cicatridina is defined by the product's instructions. These instructions establish standardized parameters for the various formulations containing the active component, Sodium Hyaluronate.

Administration Scope

Connection to the Official Use Protocol

The instructions establish a clear, structured usage protocol tied to the formulation's route. This framework defines the standardized frequency and duration, notably by instituting a maximum of 30 consecutive days of application, followed by a one-week suspension before reinitiating treatment, if necessary. This pattern ensures procedural consistency across the product’s range. The procedural steps are intended to ensure proper and consistent use of the medical device.

Research Evidence / Overview of Studies for Cicatridina

Research Evidence for Vulvovaginal Atrophy (VVA) and Post-Radiotherapy Changes

Research has explored the use of the product's ovule form, which was studied for Vulvovaginal Atrophy (VVA) symptoms in postmenopausal women. Studies conducted were often short-term Randomized Controlled Trials (RCTs). The outcomes monitored included measurements of physical tissue metrics, such as the Vaginal Maturation Index, and patient-reported outcomes describing perceived discomfort, including dryness and pain during intercourse. Research describes that trials reported measurements related to vaginal tissue metrics following the use of the product. Findings contribute to understanding symptom patterns, but long-term effects are not fully established for this use, as the evidence is limited by modest sample sizes.

Research Evidence for Anal Fissures

The ointment form of the product was evaluated in pilot clinical trials for anal fissures, which are conditions characterized by fluctuating symptoms. These open-label studies monitored responses over defined time intervals, typically 6 to 8 weeks. Research examined outcomes related to physical discomfort, specifically the time until the physical wound was closed and the reduction in patient-reported pain and bleeding. The certainty remains low regarding this evidence because the research involves modest sample sizes and the product was primarily used as a comparative standard, not the main treatment being tested against a placebo.

Research Evidence for General Superficial Tissue Injury and Chronic Wound Healing

This summary describes the evidence related to the product’s role in studies examining support for tissue integrity. The research base includes systematic reviews and clinical investigations, primarily focused on the core active ingredient, Sodium Hyaluronate. Studies monitored objective outcomes such as the rate of epithelialization and patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in studies related to the active ingredient's role in settings where tissue hydration and structural integrity are relevant. However, evidence quality varies across studies when comparing the product to different types of standard-of-care dressings for complex chronic wounds.

Gaps and Uncertainties in the Research Landscape

The current evidence base has several recognized research limitation frames. For VVA and anal fissures, the sample sizes were modest, and the follow-up durations were limited, meaning the data available for long-term outcomes remain insufficient. Comparative evidence is lacking against established pharmacological treatments for anal fissures, and the data for the specific combination product are not fully established across all forms.

Key Studies & References

1. Hyaluronic Acid and Skin: Its Role in Aging and Wound-Healing Processes (Review covering HA's role in epithelialization and hydration)
2. ISRCTN40732544: Open-label, multicenter clinical study to evaluate the safety and efficacy of ULKOX® OLE vs SoC (e.g., cicatridinum ointment, ointment for anal fissures) in adult patients diagnosed with anal fissures
3. ClinicalTrials.gov ID NCT06828640: Treatment of Vulvo-vaginal Atrophy (VVA) Using Vaginal Dilator in Addition to Usual Treatment (Example of VVA Trial Design/Outcomes)

Common questions about Cicatridina (FAQ)

Q: What kind of wounds is Cicatridina commonly used for?

Official research and information indicate that the product has been explored for use in supporting the healing of general superficial tissue injuries and specific conditions like anal fissures and vulvovaginal atrophy (VVA) symptoms. The general purpose is to aid in epithelialization, which is the process of tissue integrity restoration.

Q: Is Cicatridina the same as a regular antibiotic cream?

No. Official regulatory classification distinguishes Cicatridina as a Medical Device that functions as a Cicatrizant, or tissue repair agent. Its purpose is to optimize the physiological environment for healing, which is different from a systemic pharmaceutical agent like an antibiotic.

Q: What makes Cicatridina different from other wound gels?

The mechanism is based on its primary constituent, Sodium Hyaluronate. This substance forms a highly viscoelastic matrix (a temporary, elastic scaffold) at the site of application. Official documents state that this compound also binds to cell receptors, which initiates signaling to influence cell movement and growth to support the tissue repair process.

Q: Is it normal to feel a slight stinging sensation when first using Cicatridina?

A burning or stinging sensation is listed in the official safety information as a potential localized adverse reaction, especially when applied to sensitive areas. Regulatory labeling advises that if these reactions or any signs of irritation or hypersensitivity occur, medical advice should be sought for proper assessment and guidance.

Q: Can I use Cicatridina with other topical products like moisturizers?

Official labeling documents an explicit restriction against using Cicatridina simultaneously with products containing Quaternary Ammonium Compounds (QACs), such as certain antiseptics. This is because QACs cause the active ingredient to break down and lose its function. No other local or systemic interactions with other products are officially cited.

Q: Are there any ingredients in certain soaps or lotions that interact with Cicatridina?

The only class of substances that is officially restricted from use at the application site is Quaternary Ammonium Compounds (QACs). These are sometimes found in products like antiseptics and disinfectants. Co-administration with QACs is prohibited because it chemically inactivates the product.

Q: How quickly do most people expect to see results with Cicatridina?

Official research has monitored patient responses over defined time intervals. For instance, studies for conditions like anal fissures tracked outcomes over periods of 6 to 8 weeks. The speed of tissue restoration is generally linked to the specific condition being treated and the duration of use.

Q: Why do some people use Cicatridina for gynecological purposes?

Official research has explored the product’s ovule form for addressing symptoms of Vulvovaginal Atrophy (VVA) in postmenopausal women. The product is supplied in specific vaginal formulations, such as ovules and creams, for this local application.

Q: Does the shape (suppository, cream, spray) of Cicatridina mean different uses?

Yes, the product is supplied in various forms, including ointments, suppositories, ovules, and sprays, to allow for precise delivery. These different shapes correspond to specific routes of administration, such as topical/external, rectal, or vaginal, depending on the site requiring support.

Q: What is the role of the ingredients besides the main active one in Cicatridina?

The product is often a combination product, where the main active substance (Sodium Hyaluronate) is supported by botanical extracts like Centella Asiatica. Official mechanism of action information describes these complementary components as having bio-stimulatory effects that help enhance the structural support provided to the tissue.

Q: Does Cicatridina help with itching or discomfort related to a wound?

Official clinical studies for uses such as vulvovaginal atrophy and anal fissures have monitored patient-reported outcomes related to perceived discomfort and pain. The intended purpose is to support tissue repair and epithelialization.

Q: Is Cicatridina safe to use on delicate skin areas?

The product is approved for use on sensitive mucous membranes, including the rectal and vaginal areas, via specific formulations. However, official information notes a possibility of localized reactions such as irritation or stinging in these sensitive areas.

Q: Is it true that Cicatridina can be used on mucous membranes?

Yes. The official routes of administration are defined as Topical/External, Rectal (Suppository), or Vaginal (Ovule, Cream), confirming that the product is intended for application on mucous membranes.

Q: Is there a different formulation of Cicatridina for different age groups?

The topical forms, such as the ointment and spray, are officially indicated for use in both adults and children. Regulatory labeling does not document different concentrations or formulations that are specifically based on age group.

Q: Can people with very sensitive skin or eczema use Cicatridina?

Official eligibility rules focus on the single absolute exclusion of a known hypersensitivity or allergy to any of the product's components. The regulatory labeling does not document specific restrictions based on chronic skin conditions like eczema.

Q: Is Cicatridina approved by the FDA or EMA?

Cicatridina is primarily designated as a Medical Device and holds the European conformity mark (CE 0373). This device classification pathway is different from that of a systemic drug that requires full drug approval from agencies like the European Medicines Agency (EMA) or the US Food and Drug Administration (FDA).

Q: What kind of studies have been done on Cicatridina?

Research exploring the product has included studies such as short-term Randomized Controlled Trials (RCTs) for applications like VVA, as well as pilot clinical trials and systematic reviews that focus on the product's active ingredient, Sodium Hyaluronate.

Q: Is there a specific warning about Cicatridina and sun exposure?

Official regulatory information, including safety and precaution sections, does not cite a specific warning regarding photosensitivity or sun exposure while using Cicatridina products.

Q: What is the difference between Cicatridina cream and ointment, if both exist?

Official regulatory quick facts list the available forms as Ointment, Suppository (Ovule), and Spray. The official content does not document a separate 'cream' formulation to compare against the ointment.

Q: Can I apply makeup or sunscreen over Cicatridina?

Official labeling documents an explicit restriction against co-administration with products containing Quaternary Ammonium Compounds (QACs). No other specific local or systemic interactions with cosmetic products like makeup or sunscreen are officially cited.

--UN-

Q: Can Cicatridina be used by patients with diabetes?

The product is for local application and has a non-systemic mode of action. No restrictions or warnings related to systemic organ function or chronic conditions such as diabetes are documented in the official regulatory labeling.

Q: Does Cicatridina need to be refrigerated or stored in a specific way?

Official instructions define storage conditions, requiring the product to be stored below 25 C (77 F) and kept protected from light, moisture, and freezing. Refrigeration is not cited as a specific requirement.

Q: Can I use Cicatridina on areas of skin that have recently had a procedure like a tattoo?

The product's general purpose is to support tissue repair and aid in the healing process of general superficial tissue injuries. Official documentation does not, however, provide specific guidance or recommendations on use following cosmetic procedures like tattooing.

Q: Are there any known warnings about Cicatridina and liver or kidney conditions?

The product's non-systemic mode of action means its eligibility rules focus on local factors. No restrictions or warnings related to systemic organ function, such as hepatic (liver) or renal (kidney) impairment, are documented in the official regulatory labeling.

Q: Are there any known issues with using Cicatridina long-term?

Official instructions institute a maximum of 30 consecutive days of application, after which a one-week suspension of treatment is required before use can be reinitiated. Continuous application exceeding 30 days requires suspension of treatment, and official guidelines advise seeking a medical consultation for reassessment.

Storage and Disposal Requirements

Official labeling defines precise conditions to maintain product stability and ensure safe handling.

For disposal, unused or expired Cicatridina must be handled according to local regulatory guidelines for pharmaceutical waste. The product should not be discarded into household trash or wastewater to ensure proper environmental handling, as mandated by official disposal instructions.